Search company, investor...

Predict your next investment

Asset/Investment Management
merro.co

Portfolio Exits

1

About Merro

Merro is an investment holding company that focuses on online marketplace businesses with network effects in developing markets.

Headquarters Location

Sweden

Want to inform investors similar to Merro about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Merro News

Merro Pharmaceutical Co Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 25102017 Prices from USD $250

Nov 9, 2017

Merro Pharmaceutical Co Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25102017] Prices from USD $250 20:57 EST 8 Nov 2017 | BioPortfolio Reports Summary Merro Pharmaceutical Co Ltd Merro Pharma is a manufacturer of chemical medicines. The company offers biological medicine, Chinese traditional medicine and herbal medicine. Its products comprise amifostine, roxithromycin, famciclovir, guaifensin, azithromycin, dextromethorphan hydrobromide, azelastine hydrochloride and pantoprazole sodium . Merro Pharma also develops and manufactures national essential drugs, generic drugs and biomedicines. The company's products are used in the therapeutic areas of ulcer, antibiotics, antineoplastic, antiallergy, codeine and codeine. It operates in China and the US. Merro Pharma is headquartered in Dalian, China. Merro Pharmaceutical Co Ltd Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Merro Portfolio Exits

1 Portfolio Exit

Merro has 1 portfolio exit. Their latest portfolio exit was Hemnet on April 27, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/27/2021

IPO

$99M

Public

3

Date

4/27/2021

Exit

IPO

Companies

Valuation

$99M

Acquirer

Public

Sources

3

Merro Acquisitions

1 Acquisition

Merro acquired 1 company. Their latest acquisition was Hemnet on December 16, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/16/2016

$99M

Acq - Fin

4

Date

12/16/2016

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acq - Fin

Sources

4

Merro Team

3 Team Members

Merro has 3 team members, including , .

Name

Work History

Title

Status

Michael Lahyani

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Michael Lahyani

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.